Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

84.95 0.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.95

Max

84.95

Põhinäitajad

By Trading Economics

Sissetulek

7M

-121M

Müük

14M

25M

Aktsiakasum

-1.14

Kasumimarginaal

-481.149

Töötajad

594

EBITDA

-4.7M

-131M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+0.72% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

148M

9B

Eelmine avamishind

84.82

Eelmine sulgemishind

84.95

Uudiste sentiment

By Acuity

42%

58%

120 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. sept 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2. sept 2026, 23:51 UTC

News

Mitek Systems Inc. won first place in the Image category of the 2026 LivDet-Face competition, boosting shares significantly higher in after-hours trading.

2. sept 2026, 23:51 UTC

News
Social Media

Uber Technologies Inc. shares are higher in after-market hours following its abrupt exit from Nigeria and plans to lay off over 3,000 employees globally.

2. sept 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

2. sept 2026, 23:51 UTC

News

NWPX Infrastructure acquires Serpentix Conveyor, enhancing its wastewater treatment portfolio. Shares are trading higher in after-market hours following the announcement.

2. sept 2026, 23:46 UTC

News
Social Media

Zoom Communications appoints Jeff Epstein to its Board of Directors, effective immediately. Shares are trading higher in after-market hours amid leadership changes.

2. sept 2026, 23:41 UTC

News
Correlated Moves

nCino Inc will participate in the Piper Sandler Growth Frontiers Conference on September 16, 2026. Shares are higher in after-market trading.

2. sept 2026, 23:36 UTC

News

Phreesia shares declined after reporting second-quarter revenues of $129.5 million, while earnings per share of $0.03 missed expectations of $0.09.

2. sept 2026, 23:31 UTC

News

Genworth Financial announced a $500 million share repurchase program, with shares trading higher in after-market hours.

2. sept 2026, 23:31 UTC

News

Capital Southwest Corp increased its credit facility commitments to $595 million and extended the maturity to September 2031. Shares are higher in after-market trading.

2. sept 2026, 23:26 UTC

News

Sprinklr Inc shares are higher in after-market trading ahead of a meeting with DA Davidson on September 10, signaling potential strategic discussions.

2. sept 2026, 23:16 UTC

News
Correlated Moves

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

2. sept 2026, 23:06 UTC

News
Social Media

JPMorgan Chase has reduced financing to Jane Street amid competition in the bond market, with shares trading near unchanged in after-market hours.

2. sept 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

2. sept 2026, 23:06 UTC

News
Correlated Moves

The U.S. Justice Department disrupted the Sality botnet, linked to cryptocurrency theft, contributing to CrowdStrike's higher shares in after-market hours.

2. sept 2026, 23:02 UTC

News
Social Media
Event

Broadcom Inc. shares fell in after-market trading following third-quarter earnings. Fourth-quarter revenue guidance of $34.8 billion missed consensus expectations of $35.05 billion.

2. sept 2026, 23:02 UTC

News

C3.ai Inc reported a fiscal Q1 net loss of $92.8 million and projected second-quarter revenue below expectations, contributing to a decline in after-market hours.

2. sept 2026, 23:02 UTC

News
Event
Social Media

Five Below Inc. shares rose in after-market trading after strong Q2 earnings and a $600 million share repurchase program announcement. Revenue guidance was also raised.

2. sept 2026, 23:02 UTC

News
Social Media

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

2. sept 2026, 23:02 UTC

News
Social Media

Snowflake Inc's stock rose in after-market trading following strong Q2 results, with adjusted EPS of $0.62 and revenue of $1.55 billion exceeding expectations.

2. sept 2026, 23:02 UTC

News

Kroger Co shares traded lower in after-market hours following the appointment of Mark Ibbotson as Executive Vice President and Chief Store Operations Officer.

2. sept 2026, 23:02 UTC

News
Social Media

NetApp Inc. shares declined in after-market trading following its earnings report, despite record revenues of $2.03 billion and raised fiscal year 2027 guidance.

2. sept 2026, 23:02 UTC

News

Ollie's Bargain Outlet updated its fiscal year 2026 EPS guidance, projecting $4.570 to $4.650, exceeding the consensus estimate. Shares are higher in after-market trading.

2. sept 2026, 23:01 UTC

News
Social Media

AeroVironment secures a $464.8 million U.S. Army contract for laser systems, boosting after-market shares amid positive revenue growth projections of $2.7 billion by 2028.

2. sept 2026, 23:01 UTC

News

Mirion Technologies shares rose in after-market trading following CFO Brian Schopfer's purchase of 20,000 shares for $312,000, increasing his total ownership to 1.33 million shares.

2. sept 2026, 23:01 UTC

News

Matrix Service Co's stock is lower in after-market hours following a fourth-quarter earnings miss, with adjusted EPS at $0.16 against a $0.20 estimate.

2. sept 2026, 23:01 UTC

News

Argan Inc reported record revenue of $384 million and net income of $53.3 million in Q2, driving shares sharply higher in after-market hours.

2. sept 2026, 23:01 UTC

News
Social Media
Event

PVH Corp reported second-quarter adjusted EPS of $3.70, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

2. sept 2026, 23:01 UTC

News
Social Media

Methode Electronics reported a wider net loss of $11.4 million for Q1 fiscal 2027, leading shares to trade lower in after-market hours.

2. sept 2026, 23:01 UTC

News
Event
Social Media

Tillys Inc shares rose in after-hours trading following strong Q2 results, with EPS of $0.27 surpassing estimates and revenue of $163.5 million.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

0.72% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  0.72%

Kõrge 95 USD

Madal 80 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

13 ratings

2

Osta

11

Hoia

0

Müü

Sentiment

By Acuity

120 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat